Mounjaro and visceral fat: what the clinical evidence actually shows

Step 1, understanding why visceral fat is different from other body fat

Not all fat behaves the same way. Subcutaneous fat sits just beneath the skin (the kind you can pinch at the waist) and while excess amounts matter for health, it is the fat you cannot see that carries the sharper metabolic risk. Visceral fat wraps around internal organs: the liver, the kidneys, the intestines. Because it sits so close to the portal bloodstream, it releases fatty acids and inflammatory signals directly into circulation, raising the likelihood of insulin resistance, raised triglycerides, and cardiovascular strain.

Raised visceral fat is associated with metabolic syndrome even in people whose overall BMI sits in a nominally healthy range, which is one reason body weight alone is an incomplete picture of risk. When researchers measure visceral fat directly (typically through MRI or CT imaging in clinical trials) they can distinguish how much of a drug's effect falls on this deeper compartment versus the fat sitting just below the skin. That distinction matters, because losing subcutaneous fat is cosmetically visible but losing visceral fat has the larger effect on metabolic health markers.

The NHS tirzepatide medicines page explains the broad weight-management indication; the evidence on visceral fat specifically comes from imaging analyses conducted within the larger SURMOUNT trial programme.

Step 2, how tirzepatide's dual mechanism affects fat distribution

Mounjaro contains tirzepatide, a molecule that activates two gut-hormone receptors at once: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1. No other weight-management medicine licensed in the UK works on both pathways simultaneously. GLP-1 activation slows gastric emptying and signals fullness to the brain; GIP activation appears to affect energy storage in adipose tissue and may influence how fat depots respond to treatment. The combined effect produces appetite suppression alongside changes in how the body manages its fat reserves.

Visceral adipose tissue is metabolically more responsive than subcutaneous fat, it turns over faster and is more sensitive to hormonal signals. This may partly explain why trials involving tirzepatide for visceral fat reduction show a disproportionate effect on the deep compartment. In body composition analyses from the SURMOUNT programme, visceral fat area fell by a larger percentage than total fat mass, meaning the treatment preferentially depleted the compartment that carries the greatest metabolic burden. You can read more about how this plays out in practice on our page covering whether tirzepatide burns visceral fat.

These effects do not occur in isolation. Lifestyle changes (reduced calorie intake, maintained protein, regular activity) remain part of the licensed treatment package and likely compound the visceral fat effect independently.

Step 3, what the trial data show, and what they cannot tell you

SURMOUNT-1 (published in the New England Journal of Medicine, 72 weeks, 2,539 adults with obesity but without type 2 diabetes) remains the primary evidence base. At the 15mg dose, average body-weight reduction reached around 20–21%. Sub-analyses reported that visceral fat area, measured by imaging in a subset of participants, fell by a proportion exceeding the overall fat mass reduction, a pattern consistent with the dual-receptor mechanism described above.

What the data cannot do is tell you precisely how much visceral fat you as an individual will lose, or over what timescale. Results varied meaningfully across participants in the trial. A prescriber's job is partly to contextualise these population-level findings against your own history, weight trajectory, and metabolic profile. The SURMOUNT-5 trial later compared tirzepatide directly against semaglutide 2.4mg over 72 weeks and reported greater average weight reduction with tirzepatide, relevant context for anyone comparing medicines, covered in more depth on our Mounjaro fat loss page.

One practical question people raise is about treatment cost alongside the clinical picture. If that is on your mind, our Mounjaro prices page sets out how private treatment is structured and what a single transparent price typically covers.

Step 4 (what this means for someone considering treatment

If visceral fat is driving your interest in Mounjaro, you are asking the right question) and the honest answer is that the evidence supports a meaningful effect, not a certain one. If you have been looking into what is sometimes called the fat jab, Mounjaro is the version of that conversation most grounded in clinical trial data on visceral reduction specifically. Treatment starts at 2.5mg and is titrated by your prescriber over subsequent months; the 2.5mg pen is a settling-in dose, designed to let your body adjust rather than to produce the effects seen at higher doses in trials.

At nume, a real prescriber reads your consultation answers the same day, not a scoring algorithm. If you order before midday on a working day and your consultation is approved, your treatment is dispatched the same day and arrives free the next working day with DPD, in plain packaging. Our clinical team page gives you a clearer picture of who is reviewing your case. Eligibility is assessed individually: the licensed threshold is a BMI of 30 or above, or 27 or above alongside a weight-related condition such as high blood pressure, type 2 diabetes, or raised cholesterol, though meeting those numbers does not automatically mean treatment is suitable. Lower thresholds apply for some ethnic backgrounds under UK guidance.

Pregnancy, breastfeeding, and active plans to conceive mean treatment is not appropriate; the same applies to those under 18. If you have questions about what the process involves, our FAQs cover the most common ones, and our contact page connects you with our team directly. A good starting point is to explore our weight-loss treatment overview before you decide, and if you want a fuller picture of how Mounjaro affects belly fat specifically, that page walks through what the imaging evidence shows about the abdominal compartment. People researching fat jabs will also find Mounjaro discussed there alongside how it compares with other injectable options.

Speak to our prescribers to find out whether Mounjaro is clinically suitable for you. Start your free consultation here.